Agomelatine treatment of major depressive disorder

Annals of Pharmacotherapy

Volumn 42, Issue 12, 2008, Pages 1822-1831

  Dolder, Christian R ^a,b   Nelson, Michael ^a   Snider, Morgan ^c  

^a WINGATE UNIVERSITY   (United States)

^b Carolinas Medical Center NorthEast   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Agomelatine; Major depressive disorder; Pharmacology

Indexed keywords

AGOMELATINE; ANTIDEPRESSANT AGENT; MELATONIN; MELATONIN 1 RECEPTOR; MELATONIN 2 RECEPTOR; MELATONIN RECEPTOR; MIRTAZAPINE; PAROXETINE; RAMELTEON; SEROTONIN 2C RECEPTOR; SEROTONIN UPTAKE INHIBITOR; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ABDOMINAL PAIN; ANXIETY; BIPOLAR DEPRESSION; DEPRESSION; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SAFETY; FIRST PASS EFFECT; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; INSOMNIA; MAJOR DEPRESSION; MEDLINE; MOOD DISORDER; NAUSEA; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; RHINOPHARYNGITIS; SEASONAL AFFECTIVE DISORDER; SEXUAL DYSFUNCTION; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; WEIGHT CHANGE; WITHDRAWAL SYNDROME; XEROSTOMIA;

ACETAMIDES; ANIMALS; ANTIDEPRESSIVE AGENTS; CYTOCHROME P-450 ENZYME SYSTEM; DEPRESSIVE DISORDER, MAJOR; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, MELATONIN; SEROTONIN ANTAGONISTS;

EID: 57449090148     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1L296     Document Type: Review

References (65)

1. Scott J, Dickey B. Global burden of depression: the intersection of culture and medicine. Br J Psychiatry 2003;183:92-4.
2. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003;289:3095-105.
3. Angst F, Stassen HH, Clayton PJ, Angst J. Mortality of patients with mood disorders: follow-up over 34-38 years. J Affect Disord 2002;68:167-81.
4. Mann JJ. The medical management of depression. N Engl J Med 2005;353:1819-34.
5. Moldin SO, Scheftner WA, Rice JP, Nelson E, Knesevich MA, Akiskal H. Association between major depressive disorder and physical illness. Psychol Med 1993;23:755-61.
6. Gameroff MJ, Olfson M. Major depressive disorder, somatic pain, and health care costs in an urban primary care practice. J Clin Psychiatry 2006;67:1232-9.
7. Papakostas GI, Petersen T, Denninger JW, et al. Psychosocial functioning during the treatment of major depressive disorder with fluoxetine. J Clin Psychopharmacol 2004;24:507-11.
8. Schonfeld WH, Verboncoeur CJ, Fifer SK, Lipschutz RC, Lubeck DP, Buesching DP. The functioning and well-being of patients with unrecognized anxiety disorders and major depressive disorder. J Affect Disord 1997;43:105-19.
9. Karasu TB, Gelenberg A, Merriam A, Wang P. Practice guideline for the treatment of patients with major depressive disorder. 2nd ed. Arlington, VA: American Psychiatric Association, 2000.
10. Judd LL, Akiskal HS, Maser JD, et al. A prospective 12-year study of subsyndromal and syndromal depressive symptoms in unipolar major depressive disorders. Arch Gen Psychiatry 1998;55:694-700.
11. Hierholzer R. Remission rates for depression in STAR*D study. Am J Psychiatry 2006;163:1293-4.
12. Review of the pharmacologic management of depression. J Clin Psychiatry 2006;67:478-89.
13. 1A receptors in the rat brain. Neuropharmacology 2004;47:515-26.
14. Bloom FE. Neurotransmission and the central nervous system. In: Brunton L, Lazo J, Parker K, eds. Goodman & Gilman's the pharmacological basis of therapeutics. 15th ed. New York: McGraw-Hill, 2006:317-40.
15. Yous S, Andrieux J, Howell HE, et al. Novel naphthalenic ligands with high affinity for the melatonin receptor. J Med Chem 1992;35:1484-6.
16. Turek FW, Gillette MU. Melatonin, sleep, and circadian rhythms: rationale for development of specific melatonin agonists. Sleep Med 2004;5:523-32.
17. Witt-Enderby PA, Bennett J, Jarzynka MJ, Firestine S, Melan MA. Melatonin receptors and their regulation: biochemical and structural mechanisms. Life Sci 2003;72:2183-98.
18. Martinet L, Guardiola-Lemaitre B, Mocaer E. Entrainment of circadian rhythms by S-20098, a melatonin agonist, is dose and plasma concentration dependent. Pharmacol Biochem Behav 1996;54:713-8.
19. Reppert SM. Melatonin receptors: molecular biology of a new family of G protein-coupled receptors. J Biol Rhythms 1997;12:528-31.
20. McGechan A, Wellington K. Ramelteon. CNS Drugs 2005;19:1057-65.
21. Fuchs E, Simon M, Schmelting B. Pharmacology of a new antidepressant: benefit of the implication of the melatonergic system. Int Clin Psychopharmacol 2006;21(suppl 1):S17-20.
22. Jindal RD, Thase ME. Treatment of insomnia associated with clinical depression. Sleep Med Rev 2004;8:19-30.
23. Weibel L, Turek FW, Mocaer E, Van Reeth O. A melatonin agonist facilitates circadian resynchronization in old hamsters after abrupt shifts in the light-dark cycle. Brain Res 2000;880:207-11.
24. Conway S, Canning SJ, Howell HE, et al. Characterisation of human melatonin mt(1) and MT(2) receptors by CRE-luciferase reporter assay. Eur J Pharmacol 2000;390:15-24.
25. Ying S-W, Rusak B, Delagrange P, Mocaër E, Renard P, Guardiola-Lemaître B. Melatonin analogues as agonists and antagonists in the circadian system and other brain areas. Eur J Pharmacol 1996;296:33-42.
26. Krauc K, Cajochen C, Mori D, Graw P, Wirz-Justice A. Early evening melatonin and S-20098 advance circadian phase and nocturnal regulation of core body temperature. Am J Physiol 1997;272(4 pt 2):R1178-88.
27. Leproult R, Van Onderbergen A, L'Hermite-Baleriaux M, Van Cauter E, Copinsc G. Phase-shifts of 24-h rhythms of hormonal release and body temperature following early evening administration of the melatonin agonist agomelatine in healthy older men. Clin Endocrinol 2005;63:298-304.
28. 2C receptor. Psychopharmacology 1996;126:234-40.
29. Millan MJ, Lejeune F, Gobert A. Reciprocal autoreceptor and heteroreceptor control of serotonergic, dopaminergic and noradrenergic transmission in the frontal cortex: relevance to the actions of antidepressant agents. J Psychopharmacol 2000;14:114-38.
30. Bristow LJ, O'Connor D, Watts R, Duxon MS, Hutson PH. Evidence for accelerated desensitisation of 5-HT(2C) receptors following combined treatment with fluoxetine and the 5-HT(1A) receptor antagonist, WAY 100,635, in the rat. Neuropharmacology 2000;39:1222-36.
31. Di Giovanni G, De Deurwaerdere P, Di Mascio M, Di Matteo V, Esposito E, Spampinato U. Selective blockade of serotonin-2C/2B receptors enhances mesolimbic and mesostriatal dopaminergic function: a combined in vivo electrophysiological and microdialysis study. Neuroscience 1999;91:587-97.
32. Farce A, Chugunov AO, Loge C, et al. Homology modeling of MT(1) and MT(2) receptors. Eur J Med Chem 2008;43:1926-44. Epub 14 Dec 2007.
33. Zupancic M, Guilleminault C. Agomelatine: a preliminary review of a new antidepressant. CNS Drugs 2006;20:981-92.
34. Bourin M, Mocaer E, Porsolt R. Antidepressant-like activity of S 20098 (agomelatine) in the forced swimming test in rodents: involvement of melatonin and serotonin receptors. J Psychiatry Neurosci 2004;29:126-33.
35. 2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther 2003;306:954-64.
36. Papp M, Gruca P, Boyer PA, Mocaer E. Effect of agomelatine in the chronic mild stress model of depression in the rat. Neuropsychopharmacology 2003;28:694-703.
37. 2C receptors in Wistar rats. Psychopharmacology 2003;170:17-22.
38. 2C receptor blockade. Psychopharmacology 2005;177:448-58.
39. Papp M, Litwa E, Gruca P, Mocaer E. Anxiolytic-like activity of agomelatine and melatonin in three animal models of anxiety. Behav Pharmacol 2006;17:9-18.
40. Bertaina-Anglade V, la Rochelle CD, Boyer PA, Mocaer E. Antidepressant-like effects of agomelatine (S 20098) in the learned helplessness model. Behav Pharmacol 2006;17:703-13.
41. Barden N, Shink E, Labbe M, Vacher R, Rochford J, Mocaer E. Antidepressant action of agomelatine (S 20098) in a transgenic mouse model. Prog Neuropsychopharmacol Biol Psychiatry 2005;29:908-16.
42. European Medicines Agency. Evaluation of medicines for human use - refusal CHMP assessment and report for thymanax. www.emea.eu/humandocs/PDFs/ EPAR/thymanax/H-657-RAR-en.pdf (accessed 2008 Apr 23).
43. Kennedy SH, Emsley R. Placebo-controlled trial of agomelatine in the treatment of major depressive disorder. Eur Neuropsychopharmacol 2006;16:93-100.
44. Lemoine P, Guilleminault C, Alvarez E. Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine. J Clin Psychiatry 2007;68:1723-32.
45. Loo H, Hale A, D'Haenen H. Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. Int Clin Psychopharmacol 2002;17:239-47.
46. Montgomery SA, Kasper S. Severe depression and antidepressants: focus on a pooled analysis of placebo-controlled studies on agomelatine. Int Clin Psychopharmacol 2007;22:283-91.
47. 2C antagonistic properties, in major depressive disorder. Int J Neuropsychopharmacol 2007;10:661-73.
48. Kennedy SH, Rizvi S, Fulton K, Rasmussen J. A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR. J Clin Psychopharmacol 2008;28:329-33.
49. Fava M, Rush AJ, Wisniewski SR, et al. A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report. Am J Psychiatry 2006;163:1161-72.
50. McGrath PJ, Stewart JW, Fava M, et al. Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. Am J Psychiatry 2006;163:1531-41.
51. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006;163:28-40.
52. Eser D, Baghai TC, Moller HJ. Evidence of agomelatine's antidepressant efficacy: the key points. Int Clin Psychopharmacol 2007;22(suppl 2):S15-9.
53. Quera Salva MA, Vanier B, Laredo J, et al. Major depressive disorder, sleep EEG and agomelatine: an open-label study. Int J Neuropsychopharmacol 2007;10:691-6.
54. Calabrese JR, Guelfi JD, Perdrizet-Chevallier C. Agomelatine adjunctive therapy for acute bipolar depression: preliminary open data. Bipolar Disord 2007;9:628-35.
55. Lopes MC, Quera-Salva MA, Guilleminault C. Non-REM sleep instability in patients with major depressive disorder: subjective improvement and improvement of non-REM sleep instability with treatment (agomelatine). Sleep Med 2007;9:33-41.
56. Pjrek E, Winkler D, Konstantinidis A, Willeit M, Praschak-Rieder N, Kasper S. Agomelatine in the treatment of seasonal affective disorder. Psychopharmacology 2007;190:575-9.
57. National Institutes of Health. ClinicalTrials.gov. Search for clinical trials. www.clinicaltrials.gov/ct2/results?term = agomelatine (accessed 2008 Feb 15).
58. Fochtmann LG, Gelenberg AJ. Guideline watch: practice guideline for the treatment of patients with major depressive disorder. 2nd ed. Arlington, VA: American Psychiatric Association, 2005:1-15.
59. Rouillon F. Efficacy and tolerance profile of agomelatine and practical use in depressed patients. Int Clin Psychopharmacol 2006;21(suppl 1):S31-5.
60. Montgomery SA, Kennedy SH, Burrows GD, Lejoyeux M, Hindmarch I. Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study. Int Clin Psychopharmacol 2004;19:271-80.
61. Gerlach J. Withdrawal syndrome from SSRI antidepressive agents. Ugeskr Laeg 1998;160:861-2.
62. Lazowick AL, Levin GM. Potential withdrawal syndrome associated with SSRI discontinuation. Ann Pharmacother 1995;29:1284-5.
63. Mareth TR, Brown TM. SSRI withdrawal (letter). J Clin Psychiatry 1996;57:310.
64. Stahl MM, Lindquist M, Pettersson M, et al. Withdrawal reactions with selective serotonin re-uptake inhibitors as reported to the WHO system. Eur J Clin Pharmacol 1997;53:163-9.
65. 2C receptors antagonist, in the treatment of major depressive disorders. Encephale 2002;28:356-62.